Indeed with the development of spliceosome inhibitors themselves, and exciting preclinical data in other tumour types highlight a potential novel treatment strategy in combination with endocrine therapy and CDK4/6 inhibitors for patients with metastatic disease with spliceosomal gene alterations. Here, CDK4 is linked to metastatic neoplasm.